We are live on
!
Find out more
NV
Northpond Ventures Portfolio holdings
AUM
$43.7M
1-Year Est. Return
27.27%
This Fund
S&P 500
This Quarter
Est. Return
-14.93%
1 Year Est. Return
-27.27%
3 Year Est. Return
-67.31%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$286M
AUM Growth
–
Cap. Flow
+$298M
Cap. Flow
% of AUM
104.32%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
4
New
4
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ISO
IsoPlexis Corporation Common Stock
ISO
|
+$97.6M |
| 2 |
DICE
DICE Therapeutics, Inc. Common Stock
DICE
|
+$96.5M |
| 3 |
TBIO
Telesis Bio, Inc. Common Stock
TBIO
|
+$85.1M |
| 4 |
Candel Therapeutics
CADL
|
+$18.8M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
Similar funds
GF
IV
RCM
EPWM
SCMC
AS
GF
CLCM
Northpond Ventures's Q4 2021 Portfolio in Review
Q4 2021 is the first quarter with a 13F filing on record for Northpond Ventures, which disclosed 4 positions worth $286M. Its ten largest holdings account for 100% of the portfolio.
Its largest position is IsoPlexis Corporation Common Stock: 8,805,272 shares worth $80.9M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets.
- Northpond Ventures's largest Q4 2021 buy was IsoPlexis Corporation Common Stock: 8,805,272 shares worth $80.9M.
- Northpond Ventures's ten largest holdings make up 100% of its $286M portfolio in Q4 2021.
- Northpond Ventures disclosed 4 positions in Q4 2021, its first 13F filing on record.
Based on Northpond Ventures's 13F filing for Q4 2021, filed 15 Feb 2022.